Akèy › Myelom Miltip › Maryland
Etid klinik pou Myelom Miltip nan Maryland
25 etid pou Myelom Miltip ap chèche patisipan nan sit nan Maryland.
Vil nan Maryland
Tèks ofisyèl etid la (Anglè)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06904066Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT02682667Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 72 · Tout sèks · Mizajou Sep 28, 2026 · NCT03412877Tissue Collection for Studies of Lymph Cancer
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT01676805A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Hospital, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07609940A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of Maryland School of Medicine, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Johns Hopkins University School of Medicine JHUSOM, Baltimore
- Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT0639845718F-Fluciclovine PET/CT in Multiple Myeloma
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Sep 22, 2026 · NCT06103838Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Johns Hopkins Asthma & Allergy Center, Baltimore
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteEtid obsèvasyon
2 Months · Tout sèks · Mizajou Sep 16, 2026 · NCT00900198A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- University of Maryland | Greenebaum Cancer Center, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06980480A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- Maryland Oncology Hematology, Columbia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT07637578A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Bethesda
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07227311Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- The Center for Cancer and Blood Disorders (CCBD), Bethesda
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 24, 2026 · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Greater Baltimore Medical Center, Baltimore
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Jun 10, 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Greenebaum Cancer Center UM of MD, Baltimore
- John Hopkins, Baltimore
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05243797Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Maryland Oncology Hematology, Columbia
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 22, 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 5, 2025 · NCT05372354Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.